Structure Therapeutics Inc. Current Income Tax Expense (Benefit)
Structure Therapeutics Inc. (GPCR) reported Current Income Tax Expense (Benefit) of $436.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-26
- Structure Therapeutics Inc. current income tax expense (benefit) for fiscal 2025 was $436.00K, a 32.93% increase from fiscal 2024.
- Structure Therapeutics Inc. current income tax expense (benefit) for fiscal 2024 was $328.00K, a 47.75% increase from fiscal 2023.
- Structure Therapeutics Inc. current income tax expense (benefit) for fiscal 2023 was $222.00K, a 188.31% increase from fiscal 2022.
- Structure Therapeutics Inc. current income tax expense (benefit) for fiscal 2022 was $77.00K.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $436.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | $328.00K 10-K · filed 2026-02-26 |
| 2023-12-31 | $222.00K 10-K · filed 2026-02-26 |
| 2022-12-31 | $77.00K 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |